Idenix Pharmaceuticals to Present at the 2010 Wells Fargo Securities Healthcare Conference

CAMBRIDGE, Mass., June 16 /PRNewswire-FirstCall/ -- Idenix Pharmaceuticals, Inc. (Nasdaq: IDIX) announced today that Idenix management will present a corporate overview at the 2010 Wells Fargo Securities Healthcare Conference on Wednesday, June 23, 2010 at 8:00 a.m. ET at the InterContinental hotel, Boston.

The live and archived webcast of the company presentation can be accessed under "Calendar of Events" in the Idenix Investor Center at www.idenix.com.  Please log in approximately 5-10 minutes before the event to ensure a timely connection.  The archived replay will be available on the Idenix website for two weeks following the conference.  

About Idenix

Idenix Pharmaceuticals, Inc., headquartered in Cambridge, Massachusetts, is a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases. Idenix's current focus is on the treatment of patients with chronic hepatitis C infection. For further information about Idenix, please refer to http://www.idenix.com.

Idenix Pharmaceuticals Contacts:

Teri Dahlman: 617-995-9905 (media)

Jonae Barnes: 617-224-4485 (investors)



SOURCE Idenix Pharmaceuticals, Inc.

Suggested Articles

MicuRx nabbed $7.78 million from a nonprofit focused on antimicrobial resistance to push its third antimicrobial program into human trials.

The FDA has placed a phase 1/2 trial of Passage Bio’s GM1 gene therapy on clinical hold pending further assessment of the risk of its delivery device.

VBL got the green light after the committee looked at unblinded overall survival data for the second pre-planned interim analysis.